China Shineway Pharmaceutical Group Limited Cash Flow Conversion Efficiency
China Shineway Pharmaceutical Group Limited cash flow conversion efficiency. Based on the latest financial reports, China Shineway Pharmaceutical Group Limited (C1S) has a cash flow conversion efficiency ratio of 0.024x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€160.69 Million ≈ $187.86 Million USD) by net assets (€6.64 Billion ≈ $7.76 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of China Shineway Pharmaceutical Group Limited (2013–2025)
Cash flow conversion efficiency of China Shineway Pharmaceutical Group Limited from 2013 to 2025. This chart illustrates how China Shineway Pharmaceutical Group Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View China Shineway Pharmaceutical Group Limi stock price for real-time trading data and today's change.
China Shineway Pharmaceutical Group Limited Cash Flow Conversion Ratio Explained
China Shineway Pharmaceutical Group Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
China Shineway Pharmaceutical Group Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of China Shineway Pharmaceutical Group Limited ranked by their cash flow conversion efficiency. Also see C1S stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elco Ltd
TA:ELCO
|
0.006x |
|
Unusual Machines, Inc.
NYSE MKT:UMAC
|
-0.056x |
|
Fujian Longma Envi Sanitation
SHG:603686
|
0.030x |
|
Shanghai Kaibao Pharmaceutical
SHE:300039
|
0.045x |
|
S.J.S. Enterprises Limited
NSE:SJS
|
0.122x |
|
Finnair Oyj
HE:FIA1S
|
0.160x |
|
Guangdong Lvtong New Energy Electric Vehicle Technology Co. Ltd. Cl A
SHE:301322
|
N/A |
|
Ningbo Thermal Power Co Ltd
SHG:600982
|
0.071x |
Annual Cash Flow Conversion Efficiency for China Shineway Pharmaceutical Group Limited (2013–2025)
The table below shows the annual cash flow conversion efficiency of China Shineway Pharmaceutical Group Limited from 2013 to 2025. Review cash generation quality of China Shineway Pharmaceutical Group Limi to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €8.06 Billion ≈ $9.43 Billion |
€1.17 Billion ≈ $1.37 Billion |
0.145x | +12.71% |
| 2024-12-31 | €7.47 Billion ≈ $8.73 Billion |
€963.13 Million ≈ $1.13 Billion |
0.129x | -2.71% |
| 2023-12-31 | €7.03 Billion ≈ $8.22 Billion |
€932.63 Million ≈ $1.09 Billion |
0.133x | -23.75% |
| 2022-12-31 | €6.38 Billion ≈ $7.46 Billion |
€1.11 Billion ≈ $1.30 Billion |
0.174x | +45.92% |
| 2021-12-31 | €5.90 Billion ≈ $6.90 Billion |
€703.15 Million ≈ $822.06 Million |
0.119x | +8.11% |
| 2020-12-31 | €5.79 Billion ≈ $6.77 Billion |
€638.57 Million ≈ $746.55 Million |
0.110x | +73.01% |
| 2019-12-31 | €5.78 Billion ≈ $6.75 Billion |
€368.00 Million ≈ $430.23 Million |
0.064x | -31.04% |
| 2018-12-31 | €5.77 Billion ≈ $6.74 Billion |
€532.59 Million ≈ $622.65 Million |
0.092x | +9.59% |
| 2017-12-31 | €5.82 Billion ≈ $6.81 Billion |
€490.65 Million ≈ $573.62 Million |
0.084x | -35.34% |
| 2016-12-31 | €5.63 Billion ≈ $6.58 Billion |
€733.53 Million ≈ $857.57 Million |
0.130x | -7.29% |
| 2015-12-31 | €5.30 Billion ≈ $6.19 Billion |
€744.71 Million ≈ $870.64 Million |
0.141x | -11.01% |
| 2014-12-31 | €4.89 Billion ≈ $5.72 Billion |
€773.16 Million ≈ $903.90 Million |
0.158x | +34.64% |
| 2013-12-31 | €4.43 Billion ≈ $5.18 Billion |
€519.89 Million ≈ $607.80 Million |
0.117x | -- |
About China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules … Read more